Agenda Links: Precon/Day 1 | Day 3
AGENDA: DAY II
THURSDAY, SEPTEMBER 14, 2017
7:30 am
Registration Commences
DAY II MORNING PLENARY SESSION
(With Simultaneous Chinese/English/Chinese Translation)
8:00 am
Co-chair Welcome and Introductions
8:15 am
Keynote: How to Cultivate a Compliance Culture in a Large Organization
Jean-Christophe Pointeau
Country Chair, Sanofi China; Board Member, JHL Biotech; Former President, China, Bristol-Myers Squibb, Shanghai, China
Country Chair, Sanofi China; Board Member, JHL Biotech; Former President, China, Bristol-Myers Squibb, Shanghai, China
Jean-Christope Pointeau is Country Chair, Sanofi China. Jean-Christophe has over 20 years of international pharmaceutical experience in sales, marketing, medical affairs and access. He joined Sanofi China in April 2015 as General Manager of Pharma. Before joining Sanofi, Jean-Christophe held a series of positions at Bristol-Myers Squibb (BMS), most notably President of BMS China from 2011 to 2014. Jean-Christophe started his career in Rhone-Poulenc Rorer UK back in 1992. He also worked for Pfizer from 1997 to 2000. Jean-Christophe holds a Master of Healthcare Business Management from Ecole Supérieure de Commerce de Paris (ESCP) and a Master of Pharmacology from Paris-Sud University, France.
9:00 am
The Chinese Anti-Unfair Competition Law, the Legal Basis for the Government Agencies’ Enforcement Actions against the Pharmaceutical Industry
Professor Huang Yong
Competition Law Center, University of International Business and Economics; Executive Vice Chair, Expert Consultation Group, Anti-Monopoly Committee, State Council, People’s Republic of China, Beijing, China
Competition Law Center, University of International Business and Economics; Executive Vice Chair, Expert Consultation Group, Anti-Monopoly Committee, State Council, People’s Republic of China, Beijing, China
Lei Li, LLM
Partner, Sidley Austin; Former Third Secretary, Ministry of Commerce, People’s Republic of China, Beijing, China (Moderator)
Partner, Sidley Austin; Former Third Secretary, Ministry of Commerce, People’s Republic of China, Beijing, China (Moderator)
Lei Li is a partner in the firm’s Shanghai and Beijing office, focusing focuses on antitrust, FCPA compliance and commercial litigation (including trade litigation) matters. Before relocating to Beijing, Mr. Li practiced in the Firm’s New York office for three years.
Mr. Li has been working on antitrust matters in China since the launch of China’s Anti-monopoly Law in 2008, and has accumulated extensive experience in this area. He provides merger clearance advice in high-profile domestic and cross-border M&A deals and inbound joint venture transactions. He advises multinational companies on antitrust compliance matters in China in connection with their business activities (such as product distribution, product pricing, and IP licensing), as well as responding to antitrust investigations and inquiries by Chinese government agencies. Mr. Li is featured as a leading antitrust lawyer by highly-recognized bar publications, including Chambers Asia Pacific, IFLR 1000, and China Business Law Journal. He is the co-author of “Getting the Deal Through: Cartel Regulation 2016” Law Business Research Ltd (November 2015).
Mr. Li has been working on antitrust matters in China since the launch of China’s Anti-monopoly Law in 2008, and has accumulated extensive experience in this area. He provides merger clearance advice in high-profile domestic and cross-border M&A deals and inbound joint venture transactions. He advises multinational companies on antitrust compliance matters in China in connection with their business activities (such as product distribution, product pricing, and IP licensing), as well as responding to antitrust investigations and inquiries by Chinese government agencies. Mr. Li is featured as a leading antitrust lawyer by highly-recognized bar publications, including Chambers Asia Pacific, IFLR 1000, and China Business Law Journal. He is the co-author of “Getting the Deal Through: Cartel Regulation 2016” Law Business Research Ltd (November 2015).
9:30 am
Asia Pac Anti-Corruption Update Roundtable
Hwa Soo Chung, JD, MPA
Chair, Health Practice Group, Kim and Chang, Seoul, South Korea
Chair, Health Practice Group, Kim and Chang, Seoul, South Korea
Lei Li, LLM
Partner, Sidley Austin; Former Third Secretary, Ministry of Commerce, People’s Republic of China, Beijing, China
Partner, Sidley Austin; Former Third Secretary, Ministry of Commerce, People’s Republic of China, Beijing, China
Lei Li is a partner in the firm’s Shanghai and Beijing office, focusing focuses on antitrust, FCPA compliance and commercial litigation (including trade litigation) matters. Before relocating to Beijing, Mr. Li practiced in the Firm’s New York office for three years.
Mr. Li has been working on antitrust matters in China since the launch of China’s Anti-monopoly Law in 2008, and has accumulated extensive experience in this area. He provides merger clearance advice in high-profile domestic and cross-border M&A deals and inbound joint venture transactions. He advises multinational companies on antitrust compliance matters in China in connection with their business activities (such as product distribution, product pricing, and IP licensing), as well as responding to antitrust investigations and inquiries by Chinese government agencies. Mr. Li is featured as a leading antitrust lawyer by highly-recognized bar publications, including Chambers Asia Pacific, IFLR 1000, and China Business Law Journal. He is the co-author of “Getting the Deal Through: Cartel Regulation 2016” Law Business Research Ltd (November 2015).
Mr. Li has been working on antitrust matters in China since the launch of China’s Anti-monopoly Law in 2008, and has accumulated extensive experience in this area. He provides merger clearance advice in high-profile domestic and cross-border M&A deals and inbound joint venture transactions. He advises multinational companies on antitrust compliance matters in China in connection with their business activities (such as product distribution, product pricing, and IP licensing), as well as responding to antitrust investigations and inquiries by Chinese government agencies. Mr. Li is featured as a leading antitrust lawyer by highly-recognized bar publications, including Chambers Asia Pacific, IFLR 1000, and China Business Law Journal. He is the co-author of “Getting the Deal Through: Cartel Regulation 2016” Law Business Research Ltd (November 2015).
Michael K. Loucks, JD
Partner, Skadden Arps LLP; Former Acting United States Attorney, District of Massachusetts, US Department of Justice, Washington, DC, USA
Partner, Skadden Arps LLP; Former Acting United States Attorney, District of Massachusetts, US Department of Justice, Washington, DC, USA
Michael Loucks is an experienced trial and appellate attorney whose practice focuses on internal investigations and government enforcement matters in the U.S. and abroad, and on false claims act litigation in federal and state courts. Prior to joining Skadden in 2010, Mr. Loucks served as acting U.S. attorney and first assistant U.S. attorney for the District of Massachusetts. He repeatedly has been selected for inclusion in Chambers USA: and The Best Lawyers in America.
Mini vandePol, LLB
Attorney and Chair, Global Compliance and Investigations Group, Baker McKenzie, Hong Kong
Attorney and Chair, Global Compliance and Investigations Group, Baker McKenzie, Hong Kong
Mini vandePol is a Partner and the Global Chair of Baker McKenzie’s Compliance & Investigations Group based in Hong Kong. In this role, she leads a team of 900 professionals across 77 offices in 47 countries. Mini advises multi national corporate clients across a range of industries including Healthcare in relation to anti-corruption programs, risk assessments, transactional due diligence and investigations. She has engaged with anti-corruption regulators and enforcement bodies in a variety of jurisdictions including the US Department of Justice and SEC, the UK’s Serious Fraud Office, Hong Kong’s ICAC, PRC’s SAIC and the Australian Federal Police. Mini is a member of the B20 Anti-Corruption Taskforce and the World Economic Forum’s Partnering Against Corruption Initiative.
Chris Fordham
Managing Partner, Asia Pacific, Fraud Investigation & Dispute Services, Ernst & Young LLP, Hong Kong (Moderator)
Managing Partner, Asia Pacific, Fraud Investigation & Dispute Services, Ernst & Young LLP, Hong Kong (Moderator)
10:45 am
Break
11:15 am
Managing Pharmaceutical and Medical Device Risk Across the Asia Pacific Region
Kent Kedl, MA
Senior Partner, Control Risks; Former Vice President and General Manager, Technomic Asia, Shanghai, China
Senior Partner, Control Risks; Former Vice President and General Manager, Technomic Asia, Shanghai, China
Kent Kedl is a Senior Partner in Control Risks Asia Pacific. He is responsible for the Compliance, Forensics and Intelligence practice throughout Asia-Pacific and is also the Chairman of Control Risks’ Greater China and North Asia region. Kent has consulted with multi-national and local Asian corporations across all industries on a diverse range of complex risk and strategy issues and has particular experience and expertise in the healthcare, food and beverage, manufacturing and consumer products sectors across Asia-Pacific. Prior to joining Control Risks, Kent was general manager and co-owner of Technomic Asia, a market strategy consulting firm providing mergers and acquisitions advice, deal structuring and negotiations, market research and strategy planning. Kent has worked as a journalist and radio broadcaster, is a frequent contributor to Asia-based media outlets and is co-author of The China Ready Company (2006, China Pathways).
12:00 pm
Networking Luncheon
MINI SUMMITS BLOCK A: 1:30 pm – 2:45 pm
Mini Summit I: Chinese Anti-Corruption and Compliance Best Practices Roundtable
(Session in Chinese With Simultaneous Chinese/English Translation)
- The Impact China Regulatory Reforms on Compliance
- Incorporating the China Anti-Unfair Competition Amendment into a Compliance Program
1:30 pm
Introductions, Discussion and Q&A
Vanessa Han Jun
Head of Compliance, China, Novo Nordisk, Shanghai, China
Head of Compliance, China, Novo Nordisk, Shanghai, China
Vanessa Han is the Compliance Director of Novo Nordisk (China) Pharmaceuticals Co., Ltd. Vanessa has more than 12 years of combined Finance, Internal Control and Legal & Compliance experience in the Pharm industry, she has worked at China, Denmark and the US for taking a wide range of responsibility on Compliance, financial management, audit and internal control. She is experienced with setting up corporate governance with compliance mechanism, actively working with industry committee as core member for shaping industry code of conduct. Vanessa holds a combined background of Law, Finance and Charted Certificated Accountant, UK.
Christine Ng
Head, Ethics & Compliance Officer, Greater China, GSK, Shanghai, China
Head, Ethics & Compliance Officer, Greater China, GSK, Shanghai, China
Christine Ng is Head, Ethics & Compliance Officer Greater China in GSK. Christine was previously the Ethics & Compliance Officer for Consumer Healthcare, Greater China, GSK. Christine supported and played a fundamental role in the GSK China reform. As part of the reform, she was also responsible for setting the strategy and framework for third party governance and oversight in China which included the set-up of the ABAC and Third Party Audit team in China. Prior to China, Christine worked in the UK and has extensive experience in risks, internal audit and controls, finance including treasury, deal mergers and joint ventures, project management and change management. Christine is a qualified Chartered Accountant (CA) and obtained her CA in the UK.
Xi Zhang, PhD Law
Vice President & General Counsel Greater China, Bayer (China) Limited; Former General Counsel Asia, Celanese, Shanghai, China
Vice President & General Counsel Greater China, Bayer (China) Limited; Former General Counsel Asia, Celanese, Shanghai, China
Dr. Zhang Xi, was appointed as the Vice President and General Counsel for Bayer (China) Limited in November 2011. Prior to joining Bayer, she was the General Counsel for Celanese Asia, located in Shanghai. Dr. Zhang obtained a Master in law (“LL.M”) and subsequently her Ph.D. in law at the University of Tübingen/Germany.
She then started to work as an Associate for the international law firm “Beiten Burkhardt Mittl & Wegener” in Munich/Germany and in Hong Kong and established and headed the firm’s office in Beijing/China. Before Dr. Zhang joined Celanese, she worked for BASF AG and BASF (China) Company Limited and held the position of General Counsel Greater China and the Head of Legal, Tax & IP for more than 12 years.
She then started to work as an Associate for the international law firm “Beiten Burkhardt Mittl & Wegener” in Munich/Germany and in Hong Kong and established and headed the firm’s office in Beijing/China. Before Dr. Zhang joined Celanese, she worked for BASF AG and BASF (China) Company Limited and held the position of General Counsel Greater China and the Head of Legal, Tax & IP for more than 12 years.
Jonathan Shun Wah, PCLL
Senior Director, China Investigations Team Lead, Pfizer, Hong Kong
Senior Director, China Investigations Team Lead, Pfizer, Hong Kong
Jonathan Shun Wah is a Senior Director – China Investigations Lead at Pfizer Inc, based in Hong Kong. Mr. Shun Wah graduated from the University of Manchester in 2004 with a degree in BA Accounting and Law and is a qualified lawyer in Hong Kong and England & Wales. Prior to joining Pfizer, he worked in the Hong Kong offices of Orrick, Herrington & Sutcliffe and Dechert LLP. Mr. Shun Wah has been involved in FCPA and other internal investigations around Asia for the last eight years.
Lei Li, LLM
Partner, Sidley Austin; Former Third Secretary, Ministry of Commerce, People’s Republic of China, Beijing, China (Co-moderator)
Partner, Sidley Austin; Former Third Secretary, Ministry of Commerce, People’s Republic of China, Beijing, China (Co-moderator)
Lei Li is a partner in the firm’s Shanghai and Beijing office, focusing focuses on antitrust, FCPA compliance and commercial litigation (including trade litigation) matters. Before relocating to Beijing, Mr. Li practiced in the Firm’s New York office for three years.
Mr. Li has been working on antitrust matters in China since the launch of China’s Anti-monopoly Law in 2008, and has accumulated extensive experience in this area. He provides merger clearance advice in high-profile domestic and cross-border M&A deals and inbound joint venture transactions. He advises multinational companies on antitrust compliance matters in China in connection with their business activities (such as product distribution, product pricing, and IP licensing), as well as responding to antitrust investigations and inquiries by Chinese government agencies. Mr. Li is featured as a leading antitrust lawyer by highly-recognized bar publications, including Chambers Asia Pacific, IFLR 1000, and China Business Law Journal. He is the co-author of “Getting the Deal Through: Cartel Regulation 2016” Law Business Research Ltd (November 2015).
Mr. Li has been working on antitrust matters in China since the launch of China’s Anti-monopoly Law in 2008, and has accumulated extensive experience in this area. He provides merger clearance advice in high-profile domestic and cross-border M&A deals and inbound joint venture transactions. He advises multinational companies on antitrust compliance matters in China in connection with their business activities (such as product distribution, product pricing, and IP licensing), as well as responding to antitrust investigations and inquiries by Chinese government agencies. Mr. Li is featured as a leading antitrust lawyer by highly-recognized bar publications, including Chambers Asia Pacific, IFLR 1000, and China Business Law Journal. He is the co-author of “Getting the Deal Through: Cartel Regulation 2016” Law Business Research Ltd (November 2015).
Chen Yang, LLB, LLM
Partner and Head, China Life Sciences Practice, Sidley Austin LLP; Former Legislative Official, Bureau of Legislative Affairs, Chinese State Council, Beijing, China (Co-moderator)
Partner and Head, China Life Sciences Practice, Sidley Austin LLP; Former Legislative Official, Bureau of Legislative Affairs, Chinese State Council, Beijing, China (Co-moderator)
Mini Summit II: Asia Pac Medical Device Compliance Regulatory Developments and Burning Issues
1:30 pm
Introductions, Discussion and Q&A
M. Jason Brooke, JD
Director, Healthcare and Life Sciences Disputes, Regulatory, Compliance, and Investigations, Navigant; Former Board Member and General Counsel, Vasoptic Medical, Inc., Washington, DC, USA
Director, Healthcare and Life Sciences Disputes, Regulatory, Compliance, and Investigations, Navigant; Former Board Member and General Counsel, Vasoptic Medical, Inc., Washington, DC, USA
Jason Brooke is a Director in Navigant’s Healthcare and Life Sciences Disputes, Regulatory, Compliance, and Investigations (HLS DRCI) practice. Jason brings a focused expertise in the medical device industry that combines more than 15 years of experience ranging from science and technology design, development, implementation, and testing; to business strategy and operations; to legal and regulatory compliance. This experience allows Jason to offer a broad perspective on the challenges that face large and small, US and international clients throughout the product life-cycle when commercializing medical devices, mobile health technology, and clinical decision support software.
Campbell Clark, LLB, MJ
Chief Ethics and Compliance Officer, Asia Pacific, Medtronic, Covidien Private Limited; Chair, Legal, Ethics and Compliance Committee, Asia Pacific Medical Technology Association (APACMed), Singapore
Chief Ethics and Compliance Officer, Asia Pacific, Medtronic, Covidien Private Limited; Chair, Legal, Ethics and Compliance Committee, Asia Pacific Medical Technology Association (APACMed), Singapore
Giuseppe Falbo
Regional Compliance Director (APAC and Russia), Alcon Laboratories, Inc.; Former Business Practices Officer (Asia, Middle East, Africa, Latin America), Novartis International AG, Singapore
Regional Compliance Director (APAC and Russia), Alcon Laboratories, Inc.; Former Business Practices Officer (Asia, Middle East, Africa, Latin America), Novartis International AG, Singapore
Guiseppe Falbo is the Alcon (a Novartis Division) Regional Compliance Officer for Asia & Russia where he guided the Leadership team and the Commercial Heads in establishing the Compliance framework and the function in the Region. Giuseppe was previously based in Basel where for 3 years, he was responsible for the misconduct handling process across all Novartis Divisions in Asia, Middle East, Africa and Latin America. Before Novartis, Giuseppe lived in London where he ran his own due diligence & investigation company and prior to this, worked for Kroll EMEA. Giuseppe has had extensive experience with the United States Secret Service and the Italian economic police, prior to joining the private sector.
Rhys Tee
Director, Compliance and Privacy, ASPAC, Ortho Clinical Diagnostics; Former Compliance Director, Asia, Abbott Laboratories Pte. Ltd., Former Associate Director, Compliance (APAC), Allergan, Singapore (Moderator)
Director, Compliance and Privacy, ASPAC, Ortho Clinical Diagnostics; Former Compliance Director, Asia, Abbott Laboratories Pte. Ltd., Former Associate Director, Compliance (APAC), Allergan, Singapore (Moderator)
Mini Summit III: Global Data Privacy Update and the Impact to the Life Sciences Industry
1:30 pm
Introductions, Discussion and Q&A
Eric Carlson, JD
Partner, Covington & Burling LLP, Shanghai, China
Partner, Covington & Burling LLP, Shanghai, China
Eric Carlson advises clients operating in Asia on a range of anticorruption laws, including the FCPA. He has deep experience leading highly sensitive anti-corruption/FCPA investigations in Asia, including investigations presenting complex legal, political, and reputational risks. He has particular experience with the pharmaceutical and medical device industries. He also counsels clients on the corruption risks of proposed transactions, conducts anti-corruption due diligence as part of mergers, acquisitions, and joint ventures, assists companies in updating and strengthening their internal anti-corruption compliance programs. He speaks Mandarin and Cantonese and has led more than three hundred witness interviews in Chinese in 22 provinces in China, and conducted dozens of trainings in Chinese.
J. Mark Farrar, CPA, CFE, CFF
Healthcare and Life Sciences Disputes, Regulatory, Compliance and Investigations, Navigant; Former Interim Global Chief Compliance Officer, Beckman Coulter, Atlanta, GA, USA (Moderator)
Healthcare and Life Sciences Disputes, Regulatory, Compliance and Investigations, Navigant; Former Interim Global Chief Compliance Officer, Beckman Coulter, Atlanta, GA, USA (Moderator)
Mark Farrar is Managing Director at Navigant Consulting, Inc. within the Healthcare and Life Sciences Disputes, Regulatory, Compliance and Investigations Practice. Mark advises clients in the U.S., South America, Europe, and Asia on complex issues such as SEC financial accounting investigations, serving as the IRO for those companies under a CIA, defense strategies for off-label allegations, anti-bribery and anti-corruption issues, pharmaceutical sales and marketing compliance, economic damages and lost profits settlement calculations and consultation, field force monitoring, transparency advisory and data analytics, privacy compliance issues, and other various auditing and monitoring assessments.
Mark recently served as the interim global Chief Compliance Officer for a large multi-billion-dollar medical device and diagnostics company with over 50 world-wide locations. He built the compliance program and established a global team, as well as implemented a comprehensive third party due diligence system to manage the anti-bribery/ anti-corruption risk of its distributors.
Mark recently served as the interim global Chief Compliance Officer for a large multi-billion-dollar medical device and diagnostics company with over 50 world-wide locations. He built the compliance program and established a global team, as well as implemented a comprehensive third party due diligence system to manage the anti-bribery/ anti-corruption risk of its distributors.
Mini Summit IV: The Evolution of Compliance Organizations
- Feb 2017 guidance from the US Department of Justice on Effective compliance programs has moved from 7 to 11 elements – what are these key additions?
- How is our function addressing the impact of technology? on the business? in our roles?
- How are we adding an emphasis on ethics?
- How are these changes impacting the compliance function? What about our roles as leaders and strategic advisors?
1:30 pm
Introductions, Discussion and Q&A
Karen Eryou
Head, Ethics and Compliance Programs, UCB Pharma; Former Co-chair, Asia Pacific Pharma Compliance Congress, Brussels, Belgium
Head, Ethics and Compliance Programs, UCB Pharma; Former Co-chair, Asia Pacific Pharma Compliance Congress, Brussels, Belgium
Karen Eryou is currently the Head of Ethics & Compliance Programs for UCB. In this role she is responsible for the development of UCB’s program on ethical decision making as well as leading the global compliance operations group. This group includes transparency, third party management, investigations, monitoring & analytics as well as a frameworks programs which encompasses polices, procedures, training, and communication.
From 2010 – 2016, Karen was based in Shanghai, China where she built the compliance function for UCB, initially for China and later for the Asia-Pacific region.
Originally from Vancouver, Canada Karen has over 18 years of international work experience in the pharmaceutical industry including clinical operations, quality assurance, auditing & inspections, medical affairs, and business practice compliance. She has focused on business practices, ethics, and compliance topics for the past 10 years.
From 2010 – 2016, Karen was based in Shanghai, China where she built the compliance function for UCB, initially for China and later for the Asia-Pacific region.
Originally from Vancouver, Canada Karen has over 18 years of international work experience in the pharmaceutical industry including clinical operations, quality assurance, auditing & inspections, medical affairs, and business practice compliance. She has focused on business practices, ethics, and compliance topics for the past 10 years.
Jasmine Karimi, LLM
Senior Director & Counsel, APAC Illumina Inc., Immediate past President, Hong Kong Corporate Counsel Association, Singapore
Senior Director & Counsel, APAC Illumina Inc., Immediate past President, Hong Kong Corporate Counsel Association, Singapore
Jasmine Karimi has worked in law firms and MNCs in the US, UK, Canada, Hong Kong & Singapore, across diverse sectors (Media, Manufacturing, Luxury Goods and Biotech). Currently, she heads up legal and compliance across Asia Pacific for Illumina Inc. She is also part of APAC Management, Global Legal Management and leads the Women’s Leadership Network for the company in Singapore. She is admitted to practice law in England & Wales, Singapore, Canada, and Hong Kong. A firm believer in giving back, Jasmine has served on several boards and is the immediate past President of the Hong Kong Corporate Counsel Association (HKCCA). She currently sits on the SIAC Users Council. Jasmine has been named as one of the leading influential in-house lawyers in business in Asia in The Legal 500: Corporate Counsel 100 Asia 2014.
Geeta Thakerar
Legal AND Compliance consultancy professional (Asia Pacific), Former Vice President and Associate General Counsel, Asia Pacific/Japan, GlaxoSmithKline plc, Singapore
Legal AND Compliance consultancy professional (Asia Pacific), Former Vice President and Associate General Counsel, Asia Pacific/Japan, GlaxoSmithKline plc, Singapore
Ms. Thakerar is a seasoned and experienced legal and compliance UK solicitor with 17 years’ experience as regional General Counsel APAC. She has 23 years in-house pharmaceutical industry with GSK. Ms. Thakerar was previously with Kimberly Clark and was in private practice in London.
She is an experienced manager of large in house legal/compliance teams, legal budgets; external legal services spend/managing external law firms. Her experience is in project, transaction, stakeholder management and organisation skills complex matrix management and legal/regulatory/investigations (FCPA/U.K. Bribery Act advisory work). Ms. Thakerar is also experienced in business and functions (finance/tax/HR/supply chain/procurement) partner and crisis management.
She is an experienced manager of large in house legal/compliance teams, legal budgets; external legal services spend/managing external law firms. Her experience is in project, transaction, stakeholder management and organisation skills complex matrix management and legal/regulatory/investigations (FCPA/U.K. Bribery Act advisory work). Ms. Thakerar is also experienced in business and functions (finance/tax/HR/supply chain/procurement) partner and crisis management.
Sabina Sudan, LLB, LLM
ECLS-Consults (Ethics/Compliance/Legal/ Sustainability), Legal/International Compliance and Risk Management Professional, Singapore and Delhi, India; Adjunct Professor, Nanyang Technological University, Singapore & National University Of Singapore; Admitted to practice in Arizona, New Delhi & New York; Former Compliance Officer Life Sciences Industry, Singapore and Delhi, India (Moderator)
ECLS-Consults (Ethics/Compliance/Legal/ Sustainability), Legal/International Compliance and Risk Management Professional, Singapore and Delhi, India; Adjunct Professor, Nanyang Technological University, Singapore & National University Of Singapore; Admitted to practice in Arizona, New Delhi & New York; Former Compliance Officer Life Sciences Industry, Singapore and Delhi, India (Moderator)
Ms. Sudan is a Legal/International Compliance and Risk Management Professional in Singapore and Delhi, and India Adjunct Professor at the Nanyang Technological University, Business School, Singapore & National University Of Singapore School of Business. She is admitted to practice law in Arizona, New Delhi & New York. Previously, she was Vice President and Compliance Officer Life Sciences Industry.
Mini Summit V: Transparency Reporting to Prevent Corruption Risk
- Transfer of Value in Life Science Industry
- Where are the Risk Areas?
- Overview on the Latest Transparency Reporting Requirements in Asia Pacific
- How to Effectively Gather Data from Different Sources for the Transfer of Value Engagement
- Best Practices that We Can Apply from US and EU to Asia Pacific
1:30 pm
Introductions, Discussion and Q&A
Myung Soon Chung, Esq.
Partner, Health Law Group, Kim & Chang Law Firm, Seoul, South Korea
Partner, Health Law Group, Kim & Chang Law Firm, Seoul, South Korea
Myung Chung is a foreign attorney in the firm’s Healthcare Practice Group and Antitrust & Competition Practice Group. As a member of the Healthcare Practice Group, Ms. Chung represents a broad range of companies in the medical device and pharmaceutical sectors, advising on corporate, regulatory, compliance and pricing related issues. As a member of the Antitrust & Competition Practice Group, Ms. Chung advises numerous corporate clients on a wide range of antitrust law issues, with particular focus on cartels and unfair business practices.
Yota Kikuchi
Director, Compliance Rules & Management, Japan Pharma Business Unit, Takeda Pharmaceuticals; Member, Code Compliance Committee, Japan Pharmaceutical Manufacturers Association; Member, IFPMA Ethics & Business Integrity Committee (eBIC), Tokyo, Japan
Director, Compliance Rules & Management, Japan Pharma Business Unit, Takeda Pharmaceuticals; Member, Code Compliance Committee, Japan Pharmaceutical Manufacturers Association; Member, IFPMA Ethics & Business Integrity Committee (eBIC), Tokyo, Japan
Yota Kikuchi Joined Takeda Pharmaceuticals in May 2016 as Director of Compliance Rules and Management in Japan Pharma Business Unit. Prior to Joining Takeda, Yota was Manager of Ethics and Business Integrity in Sanofi Japan. Since 2008 he is a member of the Code Compliance Committee of the JPMA (Japan Pharmaceutical Manufacturing Association), and the Ethics and Business Integrity(eBIC) Committee of the IFPMA. He has been engaging in developing industry codes such as the JPMA Transparency State/Province:* Zip/Postal:* Country:* Email Address Additional Information IP: 210.169.207.233 Email: yota.kikuchi@takeda.com Page 3 of 4 Guidelines and JPMA Code of Practice in Japan, and the IFPMA Code of Practice through the activities within the associations.
Yunjoh Lee, LLM
Attorney, Kim & Chang, Seoul, South Korea
Attorney, Kim & Chang, Seoul, South Korea
Yunjoh Lee is an attorney at Kim & Chang. She practices primarily in health and antitrust and competition. Ms. Lee counsels multinational clients in the pharmaceutical, medical device and food industries on Korean regulatory compliance, corporate governance, competition law issues, and general corporate and commercial law matters. In particular, Ms. Lee counsels drug and device clients on various facets of anti-corruption compliance, such as designing and implementing effective compliance programs, employee training, monitoring, internal investigations, corrective action and remedial measures. Previously, she was a visiting attorney with Bristol-Myers Squibb, and a Researcher with Kim & Chang. She has represented pharmaceutical companies in investigations by the Korea Fair Trade Commission into alleged competition law violations relating to marketing and sales practices. She has also defended pharmaceutical companies before the Korea Fair Trade Commission and the Ministry of Food & Drug Safety on charges of illegal interactions with healthcare professionals and in criminal investigations into alleged illegal payments to healthcare professionals.
Clarissa Shen
China Head, Global Ethics & Business Integrity, Sanofi Group; Former Associate Compliance, Director, Eli Lilly China, Shanghai, China
China Head, Global Ethics & Business Integrity, Sanofi Group; Former Associate Compliance, Director, Eli Lilly China, Shanghai, China
Clarissa is VP, China Head of Global Ethics and Business Integrity, responsible for designing an effective compliance program for Sanofi China to uphold the group’s highest ethical standards. Clarissa has abundant people manager’s experiences in the area of credit and supply chain management; distributorship and agency management with MNCs such as BMS and Eli Lilly. Since 2009, Clarissa has progressed her career in the compliance function. Since Feb. 2012, Clarissa, in her current role, has taken the leadership role for Sanofi China. Clarissa has participated a number of International Congress where she became the event speakers on behalf of China Pharmaceutical Industry. The latest one is her participation as one of the key note speakers for 6th Asia Pacific Pharmaceutical and Medical Device (2016) Compliance Congress for the theme “Navigating Compliance Risks in China”. Graduated from Shanghai University, Clarissa has obtained a MBA degree from University of Canterbury, New Zealand.
Mike Zhao, MBA
Ethics and Compliance Lead, China, UCB; Former Compliance Manager, Johnson & Johnson, Shanghai, China
Ethics and Compliance Lead, China, UCB; Former Compliance Manager, Johnson & Johnson, Shanghai, China
Mr. Zhao has extensive experience in compliance, internal control and auditing. He has worked in Intel, Johnson & Johson and Fonterra as compliance lead of APAC/ China. Currently, he is Head of Ethics and Compliance of UCB China. ar. Zhao is also a member of IIA as Certified Internal Audit and Certification in Risk Management Assurance.
Joyce Wong
Managing Director, Polaris Asia-Pacific; Former General Manager, Eli Lilly Asia Inc., Hong Kong (Moderator)
Managing Director, Polaris Asia-Pacific; Former General Manager, Eli Lilly Asia Inc., Hong Kong (Moderator)
Joyce Wong is Polaris’ Managing Director for Asia-Pacific, providing compliance technology and software solutions as well as insightful consulting and guidance to life scinence companies throughout the region to help companies solve their toughest compliance and transparency callenges. Joyce has more than 16 years’ experience in pharmaceutical industry, including a strong background in compliance and regulatory affairs, as well as project management, new product launch, strategic planning, marketing and business management. Prior to joining Polaris, Joyce served as General Manager for Eli Lilly Asia, Inc, responsible for managing the organization to deliver business results and achieve the highest standards across all areas of business.
2:45 pm
Transition Break
MINI SUMMITS BLOCK B: 3:00 pm – 4:15 pm
Mini Summit VI: How to Minimize Anti-Corruption Risks for Tier 2 and Tier 3 Cities and Mobile Offices
(Session in Chinese With Simultaneous Chinese/English Translation)
3:00 pm
Introductions, Panel Discussion and Q&A
Eric Carlson, JD
Partner, Covington & Burling LLP, Shanghai, China
Partner, Covington & Burling LLP, Shanghai, China
Eric Carlson advises clients operating in Asia on a range of anticorruption laws, including the FCPA. He has deep experience leading highly sensitive anti-corruption/FCPA investigations in Asia, including investigations presenting complex legal, political, and reputational risks. He has particular experience with the pharmaceutical and medical device industries. He also counsels clients on the corruption risks of proposed transactions, conducts anti-corruption due diligence as part of mergers, acquisitions, and joint ventures, assists companies in updating and strengthening their internal anti-corruption compliance programs. He speaks Mandarin and Cantonese and has led more than three hundred witness interviews in Chinese in 22 provinces in China, and conducted dozens of trainings in Chinese.
Vivian Chen, LLB
Head of Compliance, Alcon Laboratories China, A Novartis Division; Former Head of Ethics and Compliance, Greater China, Baxter Intl Inc., Beijing, China
Head of Compliance, Alcon Laboratories China, A Novartis Division; Former Head of Ethics and Compliance, Greater China, Baxter Intl Inc., Beijing, China
Vivian Chen currently workes as the Head of Compliance, Greater China for Alcon, a Novartis Divison. She is response for the whole compliance framework set up and program implement in Greater China Region. Prior to Novartis Alcon, Vivian was the Head of Ethic and Compliance for Baxter/Baxalta, Greater China and Compliance Officer for Novartis Vaccines & Diagnosis, Greater China.
Chen Yang, LLB, LLM
Partner and Head, China Life Sciences Practice, Sidley Austin LLP, Former Legislative Official, Bureau of Legislative Affairs, Chinese State Council, Beijing, China
Partner and Head, China Life Sciences Practice, Sidley Austin LLP, Former Legislative Official, Bureau of Legislative Affairs, Chinese State Council, Beijing, China
Henry Yao, MA
Head of Compliance, Roche Diagnostics; Former Asia Compliance Leader, GE Energy Management, Shanghai, China
Head of Compliance, Roche Diagnostics; Former Asia Compliance Leader, GE Energy Management, Shanghai, China
Rachel B. Layburn, MBA
Partner in Charge, Forensic and Investigations Practice, KPMG China, Beijing, China (Moderator)
Partner in Charge, Forensic and Investigations Practice, KPMG China, Beijing, China (Moderator)
Rachel Layburn is a partner with KPMG China leading the forensic and investigations practice in Northern China. She is also the China head of KPMG Investigations Services. Over the past 17 years, Rachel has led over 500 forensic inquiries and assisted multinational companies, financial institutions, international and domestic law firms and government bodies for cross sector and cross border investigations involving bribery & corruption, financial statements fraud, asset tracing and recovery, as well as misappropriation of assets. Rachel is an active and core member of KPMG pharmaceutical & life science sector networks. She and her team have been focusing and providing assistance to pharma clients in China with investigations into alleged violations of the FCPA and international anti-bribery laws, sales flow data manipulation, distributor audit, channel staffing, event monitoring and best practice/gap analysis etc.
Mini Summit VII: Compliance and Ethical Issues in Patient Support Programs and Activities with Patients and Patient Advocacy Organizations
3:00 pm
Introductions, Panel Discussion and Q&A
Mohit Grover
Executive Director, Risk Consulting, Deloitte; Former Regional Chief Information Officer, Astra Zeneca Asia Pacific, Singapore
Executive Director, Risk Consulting, Deloitte; Former Regional Chief Information Officer, Astra Zeneca Asia Pacific, Singapore
Mohit Grover is an Executive Director in Risk Consulting and leads the Life Sciences & Health Care industry in Southeast Asia. With 20 years of experience in Consulting and Life Sciences industries, he possesses in-depth expertise in enabling business growth strategies, transformations in Sales & Marketing, Finance and IT functions. He has extensive experience in delivering shared services, digital, enterprise applications and outsourcing initiatives.
Ewa Holker
Legal & Compliance Director (APAC), Ferring Pharmaceuticals, Former Director, Legal & Compliance, Asia Pacific, Zimmer Biomet, Singapore
Legal & Compliance Director (APAC), Ferring Pharmaceuticals, Former Director, Legal & Compliance, Asia Pacific, Zimmer Biomet, Singapore
Ewa Holker is the Head of Legal and Compliance (Asia Pacific) at Ferring Pharmaceuticals. She is based in Singapore and provides legal and compliance leadership and support for the APAC region. Prior to joining Ferring Pharmaceuticals, she served as Director of Legal and Compliance for Asia Pacific for Zimmer Biomet and prior to that held positions in private practice law firms as well as in-house in Perth and Sydney, Australia.
Keith M. Korenchuk, JD, MPH
Partner, Arnold & Porter LLP, Washington, DC, USA (Moderator)
Partner, Arnold & Porter LLP, Washington, DC, USA (Moderator)
Keith Korenchuk counsels and advises global companies on regulatory and compliance matters worldwide, with a focus on compliance program effectiveness, compliance program implementation, operations and evaluation, and related regulatory counseling and advice. He works in a wide variety of industries and sectors including consumer products, electronics, energy, financial services, life sciences, medical device, pharmaceutical, and technology.
Since 2001, Mr. Korenchuk has been included in The Best Lawyers in America. He has developed, led, and implemented “hands-on” educational and healthcare programs that provide pharmaceuticals and healthcare services, teachers, school supplies, library resources, and computers to indigenous communities in South America for the past 12 years.
Since 2001, Mr. Korenchuk has been included in The Best Lawyers in America. He has developed, led, and implemented “hands-on” educational and healthcare programs that provide pharmaceuticals and healthcare services, teachers, school supplies, library resources, and computers to indigenous communities in South America for the past 12 years.
Mini Summit VIII: Separation and Collaboration between Medical Education and Product Promotion
3:00 pm
Introductions, Panel Discussion and Q&A
Maija Burtmanis, LLB/BSc, LLM
Regional Compliance Director, Japan/Asia Pacific, Shire, Singapore
Regional Compliance Director, Japan/Asia Pacific, Shire, Singapore
Hwee Ping Chua, LLB, LLM
Associate Vice President, International Legal & Compliance, Asia Pacific, China & Japan, Merck, Former Regional Counsel, Asia Pacific, Bristol-Myers Squibb, Singapore
Associate Vice President, International Legal & Compliance, Asia Pacific, China & Japan, Merck, Former Regional Counsel, Asia Pacific, Bristol-Myers Squibb, Singapore
Hwee Ping Chua heads up the Legal & Compliance organization for Asia Pacific, China and Japan in MSD, leading a team of approximately 30 legal and compliance professionals across the region. In the 10 years that she has been with the company, Hwee Ping has acquired extensive experience across various international markets, including a 2-year stint in the US headquarters, and has good familiarity with the legal and regulatory environment in these markets.
Prior to joining MSD, Hwee Ping was the Asia Pacific Regional Counsel of Bristol-Myers Squibb Co. for about 5 years. Hwee Ping practiced as a litigation lawyer, specializing in corporate and commercial litigation, before entering the pharmaceutical and healthcare industry as an inhouse counsel. She was also a part-time Tutor in Law at the National University of Singapore and the Singapore Institute of Legal Education. Hwee Ping is admitted to practice law in Singapore and in New York.
Prior to joining MSD, Hwee Ping was the Asia Pacific Regional Counsel of Bristol-Myers Squibb Co. for about 5 years. Hwee Ping practiced as a litigation lawyer, specializing in corporate and commercial litigation, before entering the pharmaceutical and healthcare industry as an inhouse counsel. She was also a part-time Tutor in Law at the National University of Singapore and the Singapore Institute of Legal Education. Hwee Ping is admitted to practice law in Singapore and in New York.
Christine Hu, LLM
Legal and Compliance Director, Medtronic Kanghui Orthopedics; Former Legal, Compliance & Government Affair Director, Zimmer, Beijing, China
Legal and Compliance Director, Medtronic Kanghui Orthopedics; Former Legal, Compliance & Government Affair Director, Zimmer, Beijing, China
Christine Hu heads up Legal Compliance of Medtronic Kanghui and is based in Beijing. She has 20 years extensive experience advising foreign investment in China with most recently on merger & acquisition transactions as well as compliance in healthcare industry. Christine received her undergraduate degree and Juris Master degree from the Law School of University of International Business & Economics (UIBE) and an LL.M. degree in Corporate from the School of Law of New York University.
Vivian Wu, LLB, LLM
Counsel, Fenxun Partners; Former Partner, Baker McKenzie, Beijing, China (Moderator)
Counsel, Fenxun Partners; Former Partner, Baker McKenzie, Beijing, China (Moderator)
Vivian Wu has extensive experience in advising multinational pharmaceutical and medical device companies on compliance and regulatory issues in China. In 2014, Ms. Wu worked at the Firm’s Washington DC office with our North American Compliance and Investigations Practice Group on FCPA cases. Representative clients, cases or matters Compliance – investigation, due diligence and risk assessment. She has assisted major US medical device, food, public relations, manufacturing companies, and EU based technology companies in matters including, but not limited to, alleged bribery, fraud, conflict of interest rules, false reimbursement claims and compliance issues, compliance due diligence, risk assessments and improper payments, to name a few. She has also provided industry benchmarks and recommendations to multinational clients on forming guidelines to comply with PRC anti-bribery law and FCPA.
Mini Summit IX: The Art of the Investigation: Planning, Executing and Completing Investigations
3:00 pm
Introductions, Panel Discussion and Q&A
Masood Ahmed
Vice President, Regional Compliance Officer, Asia and JPAC, Sanofi Group, Singapore
Vice President, Regional Compliance Officer, Asia and JPAC, Sanofi Group, Singapore
Masood Ahmed is the Vice President and Regional Compliance Officer, Asia & JPAC of Sanofi Group.
Masood started his career as finance professional with Beecham. He had held positions of CFO in Upjohn, Pharmacia, GSK & vice President Operations Pfizer before embarking on his role as Regional Compliance Officer with Schering-Plough.
Masood had significantly contributed in several merger and integration activities of giant pharmaceutical organizations which provided him unique opportunities of managing people, strategies and processes integration and shaping the corporate culture.
Masood has been intimately involved in the evolution of Pharmaceuticals industry’s compliance environment in challenging markets in Asia.
Masood started his career as finance professional with Beecham. He had held positions of CFO in Upjohn, Pharmacia, GSK & vice President Operations Pfizer before embarking on his role as Regional Compliance Officer with Schering-Plough.
Masood had significantly contributed in several merger and integration activities of giant pharmaceutical organizations which provided him unique opportunities of managing people, strategies and processes integration and shaping the corporate culture.
Masood has been intimately involved in the evolution of Pharmaceuticals industry’s compliance environment in challenging markets in Asia.
Calvin Chan, LLB, LLM
Partner, International Disputes and Investigations, Reed Smith, Singapore
Partner, International Disputes and Investigations, Reed Smith, Singapore
Calvin Chan is a partner in Reed Smith’s Singapore office. He has been recognized by the legal directories for his expertise in internal investigations and international arbitration. Prior to Singapore, he practiced for many years in New York, London, and Hong Kong. He is admitted to the New York and Singapore Bars, and is also a qualified solicitor of England & Wales.
Praween Chantanakomes, JD
Senior Associate, Baker & McKenzie, Bangkok, Thailand
Senior Associate, Baker & McKenzie, Bangkok, Thailand
Praween (Michael) Chantanakomes joined Baker McKenzie in 2008. He is currently active in the Corporate & Commercial, Mergers & Acquisition, Healthcare and Compliance practice groups. During his time at Baker McKenzie, Praween has been involved in assisting a number of clients in the healthcare sector, including many multinational pharmaceutical and medical device companies operating in Thailand, with their compliance work. This includes advising on various compliance issues (including advice on best-practices for compliance programs), as well as advising on and participating in compliance-related investigations and trainings.
Michael K. Loucks, JD
Partner, Skadden Arps LLP; Former Acting United States Attorney, District of Massachusetts, US Department of Justice, Washington, DC, USA
Partner, Skadden Arps LLP; Former Acting United States Attorney, District of Massachusetts, US Department of Justice, Washington, DC, USA
Michael Loucks is an experienced trial and appellate attorney whose practice focuses on internal investigations and government enforcement matters in the U.S. and abroad, and on false claims act litigation in federal and state courts. Prior to joining Skadden in 2010, Mr. Loucks served as acting U.S. attorney and first assistant U.S. attorney for the District of Massachusetts. He repeatedly has been selected for inclusion in Chambers USA: and The Best Lawyers in America.
Winnie Ho
Partner, Fraud Investigation & Dispute Services, Ernst & Young LLP, Hong Kong and Shanghai, China
Partner, Fraud Investigation & Dispute Services, Ernst & Young LLP, Hong Kong and Shanghai, China
Winnie Ho is a Partner in Ernst & Young’s Fraud Investigation & Dispute Services practice in Hong Kong and works regularly in China. She has more than 13 years of forensic accounting experience, including 6 years in Shanghai. Winnie regularly works with US listed companies, and specializes in the Life Sciences and Health Care Industry and has accumulated extensive experiences in fraud investigations in multiple industries in Hong Kong, Mainland China and in the APAC region.
Mini Summit X: Organizational Justice: One of the Pillars of a Culture of Integrity
3:00 pm
Introductions, Panel Discussion and Q&A
Maria “Maru” Quindimil, MBA
APAC Ethics and Compliance Lead, UCB Pharma; Former Executive Director, Regional Compliance Officer, Asia Pacific and India, Merck Sharp and Dohme (Asia Ltd.), Shanghai, China
APAC Ethics and Compliance Lead, UCB Pharma; Former Executive Director, Regional Compliance Officer, Asia Pacific and India, Merck Sharp and Dohme (Asia Ltd.), Shanghai, China
Maru Quindimil is currently APAC Ethics and Compliance lead for UCB. Previously, Maru was Senior Director APAC at GEC Risk Advisory LLC, the global governance, risk, integrity, reputation advisory firm serving executives, boards, investors and advisors in diverse sectors, primarily in the Americas, Europe and Africa.
Maru, the former Executive Director, Regional Compliance Officer, Asia for Merck Sharp & Dohme, Asia Ltd., led regional Compliance groups, comprising 26 professional staff in 20 Asia Pacific countries (10,000 employees) for 8 years.
Throughout a career that has spanned 27 years, Maru has applied her background in pharmaceutical and pharmacological research into the commercial pharmaceutical sector where she led the development, launch and market growth of several new products across a diverse range of geographic sectors.
Maru has led APEC Pharmaceutical sector meetings for the implementation of Pharmaceutical codes of conduct and active contributor in AP Compliance Network.
Maru, the former Executive Director, Regional Compliance Officer, Asia for Merck Sharp & Dohme, Asia Ltd., led regional Compliance groups, comprising 26 professional staff in 20 Asia Pacific countries (10,000 employees) for 8 years.
Throughout a career that has spanned 27 years, Maru has applied her background in pharmaceutical and pharmacological research into the commercial pharmaceutical sector where she led the development, launch and market growth of several new products across a diverse range of geographic sectors.
Maru has led APEC Pharmaceutical sector meetings for the implementation of Pharmaceutical codes of conduct and active contributor in AP Compliance Network.
Mike Zhao, MBA
Ethics and Compliance Lead, China, UCB; Former Compliance Manager, Johnson & Johnson, Shanghai, China
Ethics and Compliance Lead, China, UCB; Former Compliance Manager, Johnson & Johnson, Shanghai, China
Mr. Zhao has extensive experience in compliance, internal control and auditing. He has worked in Intel, Johnson & Johson and Fonterra as compliance lead of APAC/ China. Currently, he is Head of Ethics and Compliance of UCB China. ar. Zhao is also a member of IIA as Certified Internal Audit and Certification in Risk Management Assurance.
Giuseppe Falbo
Regional Compliance Director (APAC and Russia), Alcon, A Novartis Division; Former Business Practices Officer (Asia, Middle East, Africa, Latin America), Novartis International AG, Singapore (Moderator)
Regional Compliance Director (APAC and Russia), Alcon, A Novartis Division; Former Business Practices Officer (Asia, Middle East, Africa, Latin America), Novartis International AG, Singapore (Moderator)
Guiseppe Falbo is the Alcon (a Novartis Division) Regional Compliance Officer for Asia & Russia where he guided the Leadership team and the Commercial Heads in establishing the Compliance framework and the function in the Region. Giuseppe was previously based in Basel where for 3 years, he was responsible for the misconduct handling process across all Novartis Divisions in Asia, Middle East, Africa and Latin America. Before Novartis, Giuseppe lived in London where he ran his own due diligence & investigation company and prior to this, worked for Kroll EMEA. Giuseppe has had extensive experience with the United States Secret Service and the Italian economic police, prior to joining the private sector.
4:15 pm
Transition Break
MINI SUMMITS BLOCK C 4:30 pm – 5:45 pm
Mini Summit XI: Third Party (Distributor, Vendor, Alliance Partner, Government-related Associations, HCOs, etc.) Management, including Pre-evaluation, Due Diligence, Contracting, Monitoring and Payment
4:30 pm
Introductions, Panel Discussion and Q&A
Redentor Romero, JD
Associate Director, Global Third Party Compliance Program, Takeda Pharmaceuticals International; Former Regional Compliance Officer, Teva Pharmaceuticals; Former Regional Legal Counsel, AstraZeneca, Singapore
Associate Director, Global Third Party Compliance Program, Takeda Pharmaceuticals International; Former Regional Compliance Officer, Teva Pharmaceuticals; Former Regional Legal Counsel, AstraZeneca, Singapore
Redentor Romero is responsible for the Global Third Party Compliance program for Takeda Pharmaceuticals International. Prior to that, he was Regional Compliance Officer for Asia Pacific at Teva Pharmaceutical. He was also Regional Legal Counsel for the Asia Area in AstraZeneca before joining Teva. He is a lawyer by profession and had practiced law for nine years before joining corporate.
Yuet Ming Tham, JD
Partner, Sidley Austin LLP; Former Asia Pacific Regional Compliance Director, Pfizer; Former Deputy Public Prosecutor, Singapore, Hong Kong
Partner, Sidley Austin LLP; Former Asia Pacific Regional Compliance Director, Pfizer; Former Deputy Public Prosecutor, Singapore, Hong Kong
Yuet Ming Tham is a partner in Sidley’s Singapore/Hong Kong offices, and is the Head of Sidley’s Asia-Pacific Compliance and Investigations Group.
Ms. Tham has extensive experience advising a large number of major U.S./European pharmaceutical, medical devices and healthcare services companies on compliance, clinical trials, labeling, promotional and marketing regulations, as well as on a variety of contractual and commercial matters. Prior to joining Sidley, Ms. Tham was the Head of the Asia Life Sciences Group and the Asia Head of the Regulatory, Compliance and Investigations Group at another international law firm. She was previously the Asia-Pacific Regional Compliance Director for Pfizer, during which she was responsible for compliance and investigations.
Ms. Tham was most recently named the “Compliance & Investigation Lawyer of the Year 2016” by the Asian/American Lawyer Emerging Markets Awards, and her team was recognized as the “Compliance/Investigations Firm of the Year 2016”.
Ms. Tham has extensive experience advising a large number of major U.S./European pharmaceutical, medical devices and healthcare services companies on compliance, clinical trials, labeling, promotional and marketing regulations, as well as on a variety of contractual and commercial matters. Prior to joining Sidley, Ms. Tham was the Head of the Asia Life Sciences Group and the Asia Head of the Regulatory, Compliance and Investigations Group at another international law firm. She was previously the Asia-Pacific Regional Compliance Director for Pfizer, during which she was responsible for compliance and investigations.
Ms. Tham was most recently named the “Compliance & Investigation Lawyer of the Year 2016” by the Asian/American Lawyer Emerging Markets Awards, and her team was recognized as the “Compliance/Investigations Firm of the Year 2016”.
Carol Wu
Third Party Audit, Asia, Global Ethics & Compliance, GSK; Former Manager, Ethics & Compliance-China, Hospira; Former Senior Compliance Manager, AstraZeneca, Shanghai, China
Third Party Audit, Asia, Global Ethics & Compliance, GSK; Former Manager, Ethics & Compliance-China, Hospira; Former Senior Compliance Manager, AstraZeneca, Shanghai, China
Carol Wu has wide and sound knowledge and experience in compliance roles, especially in Pharma industry. She has been working with AstraZeneca, Hospira and GSK for over 10 years in different senior roles and now is the Director of Third Party Audit, Asia in GSK. She expanded her knowledge and experience in OTC and FMCG industry while she was the Ethics and Compliance Officer for GSK Consumer Health, Greater China, prior to her current role. Carol has a finance background and used to be an external auditor for KPMG before she switched to a corporate role.
Andy Bender, MS, MBA
President and Founder, Polaris, New York, NY, USA (Moderator)
President and Founder, Polaris, New York, NY, USA (Moderator)
Andy Bender is Polaris’ founder. As a hands-on executive, Andy has been involved in a wide variety of compliance-related engagements for pharmaceutical and device manufacturers, ranging from policy development and process automation to organizational change. His expertise ranges from the sales and marketing to medical and clinical departments of the client organization. Andy is still involved in many of Polaris’ client assignments, and has personally led many FMV, auditing and monitoring projects, as well as numerous international transparency reporting and HCP/O implementations. Andy has designed and developed many of the concepts, programs and methodologies that have made Polaris an international leader in the healthcare law compliance business. Polaris employs over 300 consultants State/Province:* Zip/Postal:* Country:* Email Address Additional Information IP: 65.213.232.2 Email: abenderpolaris@gmail.com Page 3 of 4 and technologists, including five healthcare law attorneys. Polaris has offices in Amsterdam, Boston, Hong Kong, New Brunswick, New York, Paris and San Francisco.
Mini Summit XII: When Will You Deploy Robot(s) in your Compliance Team?
- What is Artificial Intelligence?
- Ideas to Apply Artificial Intelligence to Compliance Analytics/Operations
- What the Future May Look Like
4:30 pm
Introductions, Panel Discussion and Q&A
Maria “Maru” Quindimil, MBA
APAC Ethics and Compliance Lead, UCB Pharma; Former Executive Director, Regional Compliance Officer, Asia Pacific and India, Merck Sharp and Dohme (Asia Ltd.), Shanghai, China
APAC Ethics and Compliance Lead, UCB Pharma; Former Executive Director, Regional Compliance Officer, Asia Pacific and India, Merck Sharp and Dohme (Asia Ltd.), Shanghai, China
Maru Quindimil is currently APAC Ethics and Compliance lead for UCB. Previously, Maru was Senior Director APAC at GEC Risk Advisory LLC, the global governance, risk, integrity, reputation advisory firm serving executives, boards, investors and advisors in diverse sectors, primarily in the Americas, Europe and Africa.
Maru, the former Executive Director, Regional Compliance Officer, Asia for Merck Sharp & Dohme, Asia Ltd., led regional Compliance groups, comprising 26 professional staff in 20 Asia Pacific countries (10,000 employees) for 8 years.
Throughout a career that has spanned 27 years, Maru has applied her background in pharmaceutical and pharmacological research into the commercial pharmaceutical sector where she led the development, launch and market growth of several new products across a diverse range of geographic sectors.
Maru has led APEC Pharmaceutical sector meetings for the implementation of Pharmaceutical codes of conduct and active contributor in AP Compliance Network.
Maru, the former Executive Director, Regional Compliance Officer, Asia for Merck Sharp & Dohme, Asia Ltd., led regional Compliance groups, comprising 26 professional staff in 20 Asia Pacific countries (10,000 employees) for 8 years.
Throughout a career that has spanned 27 years, Maru has applied her background in pharmaceutical and pharmacological research into the commercial pharmaceutical sector where she led the development, launch and market growth of several new products across a diverse range of geographic sectors.
Maru has led APEC Pharmaceutical sector meetings for the implementation of Pharmaceutical codes of conduct and active contributor in AP Compliance Network.
Junjie Yao, PhD
Associate Professor, School of computer science and software engineering, Advanced Institute of Data Analysis, East China Normal University, Shanghai, China
Associate Professor, School of computer science and software engineering, Advanced Institute of Data Analysis, East China Normal University, Shanghai, China
Junjie Yao is an Associate Professor at East China Normal University, Shanghai. His research interests are data mining, text analysis, and social media processing. He graduated from Peking University with a Ph.D degree in Computer Science, in 2013. He got his bachelor degree from Nankai University in 2007. Before joining ECNU, he spent one year as a post doctor visitor in University of California, Santa Barbara.
Chi Chen
Forensic Technology Partner, Ernst & Young LLP, Shanghai, China (Moderator)
Forensic Technology Partner, Ernst & Young LLP, Shanghai, China (Moderator)
Mr. Chi Chen is a forensic technology partner in EY’s Fraud Investigation & Dispute Services (FIDS) practice. Chi specializes in information governance and data compliance, IP and personal data privacy protection, proactive compliance monitoring and management systems, fraud detection analytics, predictive analytics, antitrust analytics, IT and cyber due diligence, and eDiscovery. All of which require in-depth analysis of large, disparate sets of financial, operational and transactional data. Chi has more than 15 years of combined advisory and audit experience in the United States, Australia and China. He has served many Fortune 500 and multinational companies in a variety of industry sectors including life sciences, manufacturing, consumer goods, industrial products, construction, technology, financial services, and telecommunications.
Mini Summit XIII: Korean Anti-Corruption and Compliance Best Practices Roundtable
4:30 pm
Introductions, Panel Discussion and Q&A
Brian Caster, JD
APAC Regional Compliance Investigations Lead, Pfizer, Tokyo, Japan
Steven Chon, MA
Director, Fraud Investigation & Dispute Services, Ernst & Young LLP, Hong Kong
Steven Chon has been with EY since 2014 as a Director of FIDS (Fraud Investigation & Dispute Services) managing projects in Korea and developing business with Korean companies in Greater China region. Steven’s first area of profession was HR working for Samsung Electronics and later entered the field of risk consulting in 2005. As a managing director of the Korea office of a multinational risk consulting firm until 2013, Steven conducted variety of fraud investigations as well as providing corporate risk consulting to multinational clients. He also managed the Korea and Japan operations of a global security firm before joining EY. State/Province:* Zip/Postal:* Country:* Email Address Additional Information IP: 202.77.40.6 Email: steven.chon@hk.ey.com Page 3 of 4 Currently Steven manages the FIDS team in Korea and contributes to the growth of the team in a rapidly changing Korean regulatory landscape.
Yunjoh Lee, LLM
Attorney, Kim & Chang, Seoul, South Korea
Yunjoh Lee is an attorney at Kim & Chang. She practices primarily in health and antitrust and competition. Ms. Lee counsels multinational clients in the pharmaceutical, medical device and food industries on Korean regulatory compliance, corporate governance, competition law issues, and general corporate and commercial law matters. In particular, Ms. Lee counsels drug and device clients on various facets of anti-corruption compliance, such as designing and implementing effective compliance programs, employee training, monitoring, internal investigations, corrective action and remedial measures. Previously, she was a visiting attorney with Bristol-Myers Squibb, and a Researcher with Kim & Chang. She has represented pharmaceutical companies in investigations by the Korea Fair Trade Commission into alleged competition law violations relating to marketing and sales practices. She has also defended pharmaceutical companies before the Korea Fair Trade Commission and the Ministry of Food & Drug Safety on charges of illegal interactions with healthcare professionals and in criminal investigations into alleged illegal payments to healthcare professionals.
Kyungsun Kyle Choi
Senior Foreign Legal Consultant, Kim & Chang Law Firm, Seoul, South Korea (Moderator)
Kyungsun Kyle Choi is a foreign attorney in the firm’s Health Practice Group and is a member of the Mergers & Acquisitions and Corporate Investigations and White Collar Practice Group. Ms. Choi represents a broad range of companies in the pharmaceutical/medical device/food/cosmetic sectors, specializing in pharmaceutical regulation, pricing and reimbursement, compliance, bribery and competition law issues relating to promotional and marketing practices in the industry, anti-counterfeiting strategies, M&A, and restructuring of business operations.
Ms. Choi’s representative work in recent years includes assisting a major multinational pharmaceutical company in a product liabilities litigation under the country’s relatively new Product Liability Law, advising the Korean subsidiary of a multinational pharmaceutical company in buy-out of a local partner in a long-standing joint-venture company, and assisting multiple multinational pharmaceutical companies to put in place or strengthen codes of conduct and compliance programs.
Ms. Choi’s representative work in recent years includes assisting a major multinational pharmaceutical company in a product liabilities litigation under the country’s relatively new Product Liability Law, advising the Korean subsidiary of a multinational pharmaceutical company in buy-out of a local partner in a long-standing joint-venture company, and assisting multiple multinational pharmaceutical companies to put in place or strengthen codes of conduct and compliance programs.
Mini Summit XIV: Fraud Trends in Asia Pacific and How Companies are Dealing with Them
4:30 pm
Introductions, Panel Discussion and Q&A
Ronald Goon
Senior Director, Business Practices & Compliance, Johnson & Johnson, Singapore
Ronald Goon is currently the Senior Director, Business Practices and Compliance at Johnson & Johnson. He is member of the Health Care Compliance & Privacy team responsible for overseeing the company’s global Third Party Intermediary due diligence program. He also supports the compliance aspect of the company’s mergers and acquisitions in the Asia-Pacific region and Johnson & Johnson’s Asia-Pacific Innovation Center.
He has over 28 years of experience in the health care industry, 18 of which have been with Johnson & Johnson. He has worked in a broad range of functional areas including quality, regulatory affairs, clinical research and sales and marketing.
He has over 28 years of experience in the health care industry, 18 of which have been with Johnson & Johnson. He has worked in a broad range of functional areas including quality, regulatory affairs, clinical research and sales and marketing.
John Tan, JD
Partner, ReedSmith; Former China Regional Compliance Director, Pfizer, Shanghai, China
John Tan co-chairs Reed Smith’s Asia Pacific Investigations Team, working with companies doing business in China and Asia on FCPA and compliance investigations, responding to government inquiries, and developing and implementing compliance programs. John also handles anti-corruption due diligence for corporate transactions.
John has handled compliance and regulatory enforcement matters for clients in multiple industries, and has particular experience with the life sciences, automotive, and energy sectors. Before joining Reed Smith, John served as China Regional Compliance Director for Pfizer. John has lived in Shanghai since 2005 and is fluent in Mandarin Chinese.
John has handled compliance and regulatory enforcement matters for clients in multiple industries, and has particular experience with the life sciences, automotive, and energy sectors. Before joining Reed Smith, John served as China Regional Compliance Director for Pfizer. John has lived in Shanghai since 2005 and is fluent in Mandarin Chinese.
Stacy Chai
Partner, Fraud Investigation and Dispute Services, Ernst & Young LLP, Singapore (Moderator)
5:45 pm
Adjournment and Networking Reception
Agenda Links: Precon/Day 1 | Day 3